From Q2 to Q3 $NOVN reduced property and equipment assets from $10.5 million down to $1.4 million. Because of this they were able to lessen their operational deficit by $1.1 million and they still slightly improved their total revenue by $1,000. Doing more with less.

This is the second quarter in a row where they drastically liquidated assets both short term and long term. They almost completely eliminated their long term assets. They are very cash heavy and they own 5.6 times more in current assets than they owe in current liabilities.

5.6 times is extraordinarily high. You’re usually hoping for a number between 1.2 and 2 as a general rule of thumb.

At the end of Q1 it was 1.99, and at the end of Q3 it was 3.97. It’s 5.6 now.

This company is financially getting ready to be bought out. To use an analogy they’re re-seeding the lawn, re-paving the drive way, removing all the furniture, cleaning the gutters, etc.. They believe they have enough cash to last through Q4 2021.

Molluscum has no FDA approved treatments & there are more than 200k cases a year in the U.S. They are well on their way in achieving FDA approval. Believe in SB206. Regardless if they strike gold in the Nitric Oxide nasal spray, their dermatology pipeline is sufficient for a

They have been working on SB206 since 2017. There have been some bumps in the road but every presentation sounds more promising than the last.

Moving on to Nitric Oxide. They are finalizing agreements with global leading drug companies to work on an intranasal treatment option against SARS-CoV-2. They are exited about their results and they’re are also requesting government grants.

Paula has made it clear that a vaccine will NOT eradicate the virus. Treatments will still be desperately needed, especially for front line workers.

R/S extension was finalized giving them until a 180-day grace period until May 3, 2021 to satisfy the $1.00 bid price requirement to maintain Nasdaq compliance.

Theres a LOT going on with $NOVN and you don’t want to miss out. This is an investment, not a trade.